Pleased to share some first images of Lutetium-177 CA-IX peptide theranostics for metastatic clear cell renal cancer #ASCO25 ASCO. Ga-68 DPI-4452 PET/CT at baseline and on-treatment shown👇 State-of-the-Science: Novel Diagnostics and Therapeutics in Renal Cell Carcinoma

Powerful talk by Rana McKay, MD, FASCO with an overview on #HIF2 inhibitors treatment landscape, #LITESPARK clinical trials comprehensive results and updates. Exciting data and future opportunities for #RCC therapy armentarium. #ASCO25 ASCO The ASCO Post Journal of Clinical Oncology Neeraj Agarwal, MD, FASCO Sumanta K. Pal, MD, FASCO

Congrats Tian Zhang, MD, MHS and Toni Choueiri, MD Alliance for Clinical Trials in Oncology for A031704/PDIGREE step 1 results and the years it took, persistence and trial design with patient support ! Largest RCC trial in the NCTN to date!

Congrats Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) and Toni Choueiri, MD Dan George for completing enrollment in the ph3 Alliance for Clinical Trials in Oncology PDIGREE, the largest cooperative group trial in mRCC #kidneycancer, protocol design, key takeaways and study timeline👇OncoAlert UroToday.com KidneyCAN

📢 #ASCO25 | NEOAVAX Ph II | High‐risk localized RCC: Neoadjuvant avelumab + axitinib × 12 wks pre‐nephrectomy in 40 pts: 30% ORR (12/40 PR), 20% median tumor downsizing; among responders, 10/12 were disease‐free at 23.5 mo median FU; no primary tumor progression.

📢 #ASCO25 | IMmotion010 Ph III | 778 pts high‑risk localized RCC: Adjuvant atezolizumab vs placebo—median DFS 57.2 mo vs 49.5 mo (HR 0.93; P = 0.50). Genomic analysis: baseline tumors from relapsing pts had ↑tumor mutational burden and PD‑L1 expression;

Deep, multi-omic analysis of adjuvant atezolizumab for ccRCC by Sumanta K. Pal, MD, FASCO and team building on prior KIM-1 studies. One take away is KIM-1 high, Teff high has longer DFS with atezo than placebo #ASCO25

📢 #ASCO25 | Biomarkers in Kidney Cancer: Are We There Yet? | Review of RCC biomarker landscape: PD‑L1, TMB, ctDNA, gene expression signatures, and microbiome insights—no validated predictors yet; integrated, multimodal strategies needed. W. Kimryn Rathmell et al. Full

📢 #ASCO25 | CM 9ER Biomarker Analysis | 651 pts aRCC: Integrative analysis of circulating (e.g., early ctDNA clearance, peripheral immune subsets) & TME (CD8+ TIL density, PD‑L1 expression) determinants of response to NIVO+CABO. High baseline CD8+ TILs & ctDNA clearance

📢 #ASCO25 | GETUG‑AFU 26 Ph II | mRCC pts (n = 96; 85 ccRCC; 68 IMDC int/poor) receiving 1L nivolumab: Baseline sMAdCAM‑1 stratified PFS/OS—high levels linked to shorter survival; pts with early sMAdCAM‑1 decline had higher ORR. By our own Renee M. Saliby et al.

Outstanding presentation by Sumanta K. Pal, MD, FASCO at #ASCO25. In IMmotion010: 📍Serum KIM-1 ➡️ strongest predictor of benefit. 📍Within pts with high KIM-1 those with high T-eff had longer DFS with atezolizumab vs placebo. OncoAlert UroToday.com City of Hope

📢 #ASCO25 | Discussion | Guts, Blood, and Tumor: The Search for Kidney Cancer Biomarkers Continues | David F. McDermott, MD, synthesizes insights from Abstracts 4509–4512—NEOAVAX neoadjuvant signals, IMmotion010 genomic relapse drivers, CM 9ER ctDNA/TME predictors, gut

Good morning! ☀️ Ready to kick off Day 3️⃣ of #ASCO25—another full day of science, collaboration, and inspiration. Let’s go!

#ASCO25 Final results of IO-based combinations in mRCC are in! See below and subsequent posts for thoughts. Video discussing these data coming soon from OncoAlert...

In the checkmate-214 ph3 trial, it is amazing to see 25% pts (intermediate-poor risk mRCC #kidneycancer ) are alive 8 years after starting treatment with ipilimumab+nivolumab. Robert Motzer MD Toni Choueiri, MD Congrats on this remarkable achievements @asco #asco25 @oncolaert UroToday.com

With all the amazing presentations at #ASCO25, just wanted to take a moment to share some of our data related to #biomarkers from the #IMmotion010 phase III study, a trial of adjuvant #atezolizumab vs pbo. A tremendous team helped me put this together, including Wenxin (Vincent) Xu

🗣️Kidney Cancer Oral Abstracts #ASCO25 👉Abs4506: Dr Toni Choueiri, MD presenting #Casdatifan + Cabo for refractory ccRCC #ARC20 n = 27 prior tx adjuv only (5/26), metastatic (1L 17/26; 2L 4/26). prior tx IO only (15/26), IO + TKI (11/26). median f/u = 2.9mo (0.1–6.8) ♦️ORR = 46%

#ASCO25 HIF inhibitor combination results. Shown below is single agent Cabo and Belzu for reference, and published HIF-based combo data. *ORR marginally higher *PFS longer but endpoint not reliable in a single-arm trial *Phase 3 trials are planned. Beating TKI may be challenging

At ASCO #ASCO25 #abs4506 Toni Choueiri, MD delivers another terrific talk 👉Results from Ph 1 ARC-20 study #kidneycancer👉Casdatifan (novel HIF-2a inhibitor) plus cabozantinib in previously treated mRCC👇promising activity, ph3 started OncoAlert UroToday.com @KidneyCAN Kidney Cancer

Terrific presentation by #VivekNarayan Ab#4507 ASCO #ASCO25 👉5-yr f/u of Ph2 LITESPARK-004👉Belzutifan shows durable activity and manageable toxicity in VHL-associated neoplasms (ORR 70% in RCC) #kidneycancer👇OncoAlert UroToday.com @kidneycancer